Global Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Abiogen Pharma SpA, Biohaven Pharmaceuticals, Grunenthal GmbH, NeuroTherpia Inc, Piramal Enterprises Ltd and others.
A Significant contribution to the Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) condition and increased access to investments is encouraging growth of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy). Further, orphan drug status, fast track designation, grants awarded and other special status for Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Pipeline candidates-
A Significant contribution to the Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) condition and increased access to investments is encouraging growth of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy). Further, orphan drug status, fast track designation, grants awarded and other special status for Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drugs
- Late phase: Phase 3 and in-approval Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drugs
- Company overview
- Snapshot
- Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Disease Overview
2.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Snapshot
2.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Drugs by Phase
2.4 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Drugs by Company
2.5 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abiogen Pharma SpA Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.2 Biohaven Pharmaceuticals Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.3 Grunenthal GmbH Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.4 NeuroTherpia Inc Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.5 Piramal Enterprises Ltd Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.6 Takeda Pharmaceutical Co Ltd Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.7 Tetra Bio-Pharma Inc Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 1 Drug Details
4.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 1 Drug Overview
4.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 2 Drug Details
5.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 2 Drug Overview
5.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 3 Drug Details
6.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 3 Drug Overview
6.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pre-clinical Phase Drug Details
7.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pre-clinical Phase Drug Overview
7.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Disease Overview
2.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Snapshot
2.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Drugs by Phase
2.4 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Drugs by Company
2.5 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abiogen Pharma SpA Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.2 Biohaven Pharmaceuticals Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.3 Grunenthal GmbH Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.4 NeuroTherpia Inc Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.5 Piramal Enterprises Ltd Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.6 Takeda Pharmaceutical Co Ltd Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
3.7 Tetra Bio-Pharma Inc Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 1 Drug Details
4.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 1 Drug Overview
4.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 2 Drug Details
5.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 2 Drug Overview
5.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 3 Drug Details
6.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 3 Drug Overview
6.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pre-clinical Phase Drug Details
7.2 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pre-clinical Phase Drug Overview
7.3 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
